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Abstract Differential display PCR was used to study the effects 
of lithium on gene expression. Four candidate genes were isolated 
and verified by Northern hybridization after 1 week treatment of 
C6 glioma cells with therapeutically relevant concentrations of 
LiCI (1 mM). Sequencing analysis revealed three previously 
unidentified cDNA fragments in addition to a sequence with 99% 
homology with the cDNA for 2',3'-cyclic nucleotide 3'- 
phosphodiesterase type II (CNPasell). Since CNPaselI is 
important in myelinogenesis and possibly neuronal growth and 
repair, the present findings suggest hat lithium treatment may 
regulate these processes. 
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I. Introduction 
Bipolar affective disorder (BD) is a common psychiatric 
disorder in which biological factors are important in the de- 
velopment of symptoms and response to drug treatment [1]. 
Specific pathophysiological processes operative in BD, how- 
ever, are still being investigated. One of the strongest clues to 
the biological basis of BD is the large body of evidence sug- 
gesting a genetic predisposition to the disorder [1,2]. Recent 
research in our laboratory and others indicates that G-pro- 
teins and possibly other components of the signal transduc- 
tion pathway play an important role in the mechanism of BD 
although the precise defect is far from clear [3-6]. 
Lithium is a highly effective treatment for BD [1,7]. It is 
widely acknowledged that in BD, chronic treatment with 
lithium (i.e. at least 1 week) is needed for its acute effects 
against mania and that long-term (i.e. several years or longer) 
treatment can markedly improve the course of the illness and 
prevent relapses of either mania or depression [7]. Further- 
more, long-term changes in neuronal synaptic function are 
related to changes of gene expression in brain which may 
underlie the effects of psychotropic drugs [8]. It has therefore 
been hypothesized that, among other effects, lithium treat- 
ment may act by altering gene expression in brain [9,10]. 
Lithium-induced changes in gene expression have been docu- 
mented in cultured cells and animal models for several years 
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[9,11]. Several studies have demonstrated that lithium alters 
the expression of the early response gene c-fos through a pro- 
tein kinase C (PKC)-mediated mechanism [12,13]. For exam- 
ple, incubation of PC-12 cells for 16 h with lithium signifi- 
cantly potentiates c-fos expression induced by the muscarinic 
agonist, carbachol. Lithium pretreatment in these cells also 
potentiates c-fos expression in response to phorbol esters, 
which directly activate PKC [13]. Chronic lithium treatment 
(i.e. a week or longer) has also been shown to reduce the 
expression of G-protein a-subunit (as and ai) but to increase 
expression of adenylyl cyclase types I and II [14-16]. It is also 
reported that lithium alters the mRNA levels of a number of 
neuropeptides [17,18]. For example, acute treatment with 
lithium enhances basal expression of the neuropeptide Y 
gene in rat hippocampus [17]. Chronic administration of 
lithium (3 weeks) increased the prodynorphin mRNA abun- 
dance in the rat striatum [18]. Considering these findings of 
lithium's effect on gene expression together, nonetheless, pro- 
vides an incomplete picture of the underlying mechanism of 
action of this drug in BD. Therefore the isolation of other 
lithium-regulated genes (LiRGs) is very important, particu- 
larly if these genes can be shown to be involved in the devel- 
opment of BD or can be shown to be functionally relevant o 
central nervous system (CNS) functioning. 
The differential display PCR (DD-PCR) technique was de- 
veloped to identify differentially expressed genes and to detect 
differences in specific mRNAs in different cell lines or after 
specific pharmacological manipulations [19-21]. We employed 
this method to screen and clone differentially expressed genes 
after administration of lithium at therapeutically relevant con- 
centration (1 mM) for 1 week in C6 glioma cells. This cell line 
was chosen since much of the earlier work on the molecular 
mechanism of mood stabilizing drugs had been carried out in 
this cell line [22,23]. This includes the recent convergence of 
findings which suggest that components of signal transduction 
pathways are regulated by lithium thereby increasing the like- 
lihood of finding a result which is physiologically relevant [24- 
26]. We report here that the expression of four genes was 
increased by lithium including 2',3'-cyclic nucleotide 3'-phos- 
phodiesterase type II (CNPaselI), the latter of which may be 
important in neuronal growth and repair. 
2. Materials and methods 
2.1. Cell culture 
C6 glioma cells were grown in medium containing Dulbecco's mod- 
ified Eagle's medium, 15% horse serum, and 2.5% fetal calf serum. 
Cells were treated for 1 week in the presence or absence of different 
concentrations of LiC1 (0.04, 0.2 and 1 mM) or NaC1 (1 mM). In 
other experiments cells were treated with therapeutically relevant con- 
centrations of two other mood stabilizers, carbamazepine (0.05 mM) 
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[7,16] and sodium valproate (0.5 mM) [7,24], and as a control for the 
monovalent Li cation, NaC1 (1 mM). 
2.2. Differential display of mRNA by PCR (DD-PCR) 
Total RNA was isolated using the Trizol reagent (Gibco Life Tech- 
nologies, Gaithersburg, MD) according to the manufacturer's proto- 
col. Chromosomal DNA was removed by digestion with RNase-free 
DNase I. Total RNA was extracted with phenol/chloroform and pre- 
cipitated in 100% ethanol at -20°C overnight. The concentration of
RNA in each sample was quantitated by measuring the OD at 260 nm 
and the purity determined by the 2601280 ratio. 3 gg of DNase-treated 
RNA was separated by electrophoresis on a denaturing 1% agarose 
gel to check the integrity of the RNA (18S and 28S bands). All 
reagents used in DD-PCR were from GenHunter Corporation (Nash- 
ville, TN) except Taq polymerase which was obtained from Perkin- 
Elmer Corp. (Branchburg, NJ). DNA-free RNA was transcribed to 
cDNA with reverse transcriptase using three different one-base-an- 
chored primers: oligo-dTG, oligo-dTA and oligo-dTC. Primers for 
PCR reaction were one of eight arbitrary decamers and one of oli- 
go-dTG, oligo-dTA or oligo-dTC. The PCR reaction mixture (20 gl) 
contained 2 gM of each primer, 25 IaM dNTP, 0.5 gM [c~-35S]dATP 
(1200 Ci/mmol) and 1 unit of Taq polymerase, and buffer supplied by 
the manufacturer (GenHunter Corp.). The PCR reaction (40 cycles) 
consisted of sequential incubations for 30 s at 94°C, for 2 min at 
40°C, for 30 s at 72°C, with a final extension for 5 min at 72°C. 
The amplified cDNAs were then separated on 6% denaturing poly- 
acrylamide gel. Gels were dried and exposed to Kodak X-omat film 
for 2 days. Differentially displayed cDNAs were then recovered from 
gel and reamplified by PCR with the same primers. The reamplified 
cDNAs were extracted from a nondenaturing 1.5"/,, agarose gel by 
QIAEX Gel Extraction Kit (QIAGEN Inc., Chatsworth, CA). 
2.3. DNA cloning and sequence analysis 
Differentially displayed PCR products were ligated into the pNo- 
TA/T7 vector at 25°C for 30 min with T4 DNA ligase (5 primer - 3 
primer, Inc., Boulder, CO). Competent bacterial cells were trans- 
formed with the ligated construct. Plasmid DNA from subclones con- 
taining inserts was then purified using a Wizard Miniprep DNA pu- 
rification system (Promega, Madison, Wyoming). Inserts were 
sequenced by the dideoxy chain-termination method [27]. Sequences 
thus derived were compared for homology to the sequences present in 
the current GenBank database through the National Center for Bio- 
technology Information with the BLASTN program [28]. 
and were reamplified, purified and named LiRG1 (128 bp), 
LiRG2 (178 bp), LiRG3 (120 bp), L iRG4 (160 bp) and 
LiRG5 (155 bp). The reamplified displayed cDNAs were 
radioactively labeled for probing Northern blots containing 
total RNA from control and 1 mM LiCl-treated cells to con- 
firm their expression in cells. The expression of LiRG1, 
LiRG2, LiRG3 and LiRG5 was increased by 1 mM LiC1 
whereas no signal was found for L iRG4 (Fig. 2). These four 
differentially expressed cDNAs were then directly cloned into 
the pNoTA/T7 cloning vector and DNA sequencing was per- 
formed. As shown in Fig. 3, the sequences of LiRG1, LiRG2, 
LiRG3 and LiRG5 revealed DNA fragments which included 
the arbitrary decamers and anchored oligo-dT primers in ad- 
dition to AATAAA (i.e. the polyadenylation signal) upstream 
of the poly A sequence. These results suggest hat the LiRG1, 
LiRG2, LiRG3 and LiRG5 cDNA fragments are from the 3' 
ends of these specific genes. The clone named LiRG5 dis- 
played 99% homology to rat CNPaseII  [31]. LiRG1, LiRG2 
and LiRG3 showed no significant homology (<85%) to any 
entry in existing nucleic acid databases available through the 
National Center for Biotechnology Information. 
To further investigate possible similarities between lithium 
and other drugs which are commonly used for treatment of 
BD, we determined the effect of therapeutically relevant con- 
centrations of sodium valproate and carbamazepine [7] on 
CNPaseII  gene expression by slot blot analysis. As shown in 
Fig. 4, 1.0 mM sodium chloride, 0.5 mM sodium valproate, 
0.05 mM carbamazepine and 0.04 mM LiC1 had no effect on 
CNPaseII gene expression. LiC1 0.2 mM and 1.0 mM signifi- 
cantly increased CNPaseII  gene expression by 25.7+9.3% 
(P<0.05, n--3) and 62.0_+ 12.6% (P<0.01, n=3). There was 
no difference in level of hybridization of ~-actin compared 
to control cells after any of these treatments. 
4. Discussion 
2.4. Northern hybridization and slot blot analysis 
Total RNA from C6 glioma cells was applied to nylon membranes 
using either a slot blot apparatus or by transfer after electrophoresis 
in 1% agarose/formaldehyde gel,and ultraviolet-cross-linked. Mem- 
branes were then pre-hybridized at 42°C for 3 h in 5×SSC, 50% 
formamide, 5xDenhardt's, 1.0% SDS, 5% dextran sulfate, salmon 
sperm DNA (100 lag/ml) and hybridized at 42°C overnight in this 
buffer with differentially displayed cDNA probes derived as described 
above, cDNA probes were labeled with [32p]dCTP by using a random 
prime labeling method [29,30]. Membranes were then washed at room 
temperature for 45 min in 1 x SSC, 0.2% SDS twice and at 58°C for 
15 min in 0.1 x SSC, 0.2% SDS twice. Membranes were exposed over- 
night at -80°C to Kodak X-Omat film with an intensifying screen. 
2.5. Analysis and interpretation of data 
All sequence data were analyzed by DNASIS sequence analysis 
program and aligned with sequences available in GenBank. Data 
from slot blot studies were obtained by densitometric analysis of 
autoradiograms with the Northern Exposure program from ImagEx- 
perts, Inc. (Oakville, Ont.). Results were expressed as percent of con- 
trol. Changes in gene expression after drug treatment were expressed 
as the mean_+ SEM from three separate xperiments. Statistical sig- 
nificance of differences between means was determined by Student's 
t-tests. 
DD-PCR revealed four differentially expressed gene prod- 
ucts after treatment with LiCI for 1 week at therapeutically 
relevant concentrations in C6 glioma cells. Although the iden- 
tity of three of these gene products is at present unknown, the 
expression of a cDNA with greater than 99% homology to the 
gene for the enzyme CNPasel I  was markedly increased after 
lithium treatment. The expression of this cDNA in cells was 
confirmed by Northern hybridization and quantitative slot 
blot analysis and was not increased by either sodium chloride 
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3. Results 
Five bands were differentially expressed between control 
and 1 mM LiCl-treated cells (Fig. 1). These differentially ex- 
pressed PCR products, i.e. LiRGs, were excised from the gels 
Fig. 1. Differential display of mRNA in the presence and absence 
of 1 mM LiC1 using multiple anchored oligo-dT and random primer 
sets. Arrows point to differentially displayed products. Five products 
show differential display between control (C) and LiC1 (Li)-treated 
cells. 
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Fig. 2. Northern blot analysis of candidate LiRGs. Total RNA was 
isolated from C6 glioma cells grown with (Li) or without (C) 1 mM 
LiC1 for 1 week. RNA (15 gg) was analyzed by Northern blot ana- 
lysis using probes prepared from products of DD-PCR (LiRG1- 
LiRG5). The positions of 18S and 28S rRNA are indicated. 
or the other drugs commonly used to treat BD (i.e. sodium 
valproate or carbamazepine at therapeutically relevant con- 
centrations [7]). These results add to the growing body of 
evidence suggesting that lithium alters gene expression in 
brain after chronic treatment which may be important in its 
action as a long-term prophylactic treatment for BD [8,9,11]. 
These results are also consistent with the current notion that 
psychotropic drug treatment may act through long-term adap- 
tational changes in the CNS to bring about their therapeutic 
effects [8]. 
CNPaseII, a myelin-associated enzyme, was among the four 
differentially expressed genes identified after lithium treatment 
in C6 glioma cells. Although the function of CNPaseII is not 
yet clear, much investigation has been done to understand its 
significance in the CNS. In vitro, CNPase hydrolyzes 2',3'- 
cyclic nucleotides to form 2'-nucleotides [32,33], however, 
2',3'-cyclic nucleotides are not known to have physiological 
relevance in mammals. In the CNS, CNPase is highly local- 
ized to the myelin sheath and oligodendroglia [34-37]. It is 
reasonable to assume that CNPase function may be related 
to differentiation of oligodendroglial cells. In this respect, it 
has been shown that elevation of brain CNPase activity in 
rodent brain occurs in parallel with myelination [38,39]. 
CNPase begins to appear earlier than myelin basic protein 
(MBP), and in rat brain CNPase activity increases to 65% of 
the adult level 20 days after birth, whereas MBP reaches only 
30% of the adult level. CNPase maintains its high activity for 1 
year after birth. Thus CNPase may have an important role in 
differentiation f oligodendroglial cells and CNS myelination. 
Molecular analysis of CNPase indicates the presence of 
several potential nucleotide- and phosphoryl-binding sites on 
the CNPase molecule [33]. For example, the amino acid se- 
quence of CNPase includes a consensus equence GXXX- 
XGK and DXXXG/A, which is found to comprise two of 
the three elements of the GTP-binding domain of G-protein 
c~-subunits [40]. This suggests that CNPase may act as a ki- 
nase-related protein. This observation has led to the specula- 
tion that CNPase may play a role in glial differentiation by 
providing a binding site for ATP. It was reported that in brain 
myelin CNPase is phosphorylated by cyclic AMP-dependent 
protein kinase and PKC and that CNPaseII is far more highly 
phosphorylated than CNPaseI [41]. These latter results sug- 
gest that CNPaseII might be a target for CNS signal trans- 
duction pathways which regulate protein phosphorylation. Of
further interest o this latter possibility is the extensive body 
of recent data which has suggested that lithium has important 
effects on such signal transduction pathways [9,11]. 
Since the exact role of CNPaseII in the CNS is not known, 
we can only speculate about the significance of increased 
CNPaseII expression after chronic lithium treatment. CNPase 
has been investigated in the pathophysiology of several dis- 
orders including multiple sclerosis. For instance, CNPase ac- 
tivity was reduced to 50% of control values in postmortem 
brain white matter samples obtained from subjects with multi- 
ple sclerosis [42]. The fact that CNPaseII is involved in cell 
differentiation and myelinogenesis raises the possibility that 
lithium treatment may lead to its therapeutic effects in BD 
by regulating one of these processes. Regulation of neuronal 
plasticity and long-term adaptational changes in CNS are 
currently under investigation astargets of psychotropic drugs, 
including lithium [8,43]. It is therefore interesting to consider 
the possibility that upregulation of CNPaseII in brain by 
lithium may result in long-term changes in CNS functioning 
which are in turn relevant for symptomatic improvement. 
A better understanding of the physiologic significance of 
CNPaseII may allow these interesting questions to be answered. 
The relevance of an effect of lithium on CNPaseII is further 
demonstrated by the previous finding of white matter ab- 
normalities in patients with BD. Patients with multiple sclero- 
LiRG1 (Unidentified) 
AAGCTTCTCAACGTATAAAGACACATTTCTGACTG 
CTATTTTTACATCAAAGAATTCATACAAATAAGAT 
GGAAAATAAAATAATAACGTTT AATAAAATTTAA 
**  * a ,  It  . t .  * * t t  
AGTTCACAGTTGTAAAAAAAAAAAGCTT 
LiRG2 (Unidentified) 
AAGCTTCTCAACGAACACATAGCATTATGTAAACT 
CTAATAATTCATTAAGTAGTGAATGAATCTTAACA 
ATTTAATGCCTTTGGGAAATAAAAGTGAAAACTG 
GCd2AA~A~TGGGCGTGAACCGCTTAC 
TAGATAATGTTCTCTAAAAATTGGCTCTGAAAAAA 
AAAAAGCTT 
LiRG3 (Unidentified) 
AAGCTTCTCAACGCAGTATAAGAATGTGATATATT 
GTATATTGGAAAGTATTTACCTTATTTATATACCT 
GAATGTTCCTATTAAACAAATAAACATATACTAAA 
* * t  t a t  
TTCTAAAAAAAAAAA~TT 
LiRG5 (99% homology to CNPaseH) 
AAGCTTTTACCGCAATGC~AAAGTCTGCTCAGTAA 
CAGGACCTTGCTAATTGGGTTGTCACCCAAGCATC 
TGGGATTTATGTTCCTACCCTCACCCTGTGTTGCCC 
ACCTGAGCAACAACTAAGACTGATACTGAAATAAA 
* I t .  t * *  
T C G T G T T A A T C C C ~ T T  
Fig. 3. Nucleotide sequence of LiRG1, LiRG2, LiRG3 and LiRG5. 
Anchored oligo-dT and arbitrary decamers are underlined. Polyade- 
nylation signal is marked with *. DNA sequence identities were de- 
termined using the BLASTN program. 
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Fig. 4. Effect of sodium valproate (VP), carbamazepine (CZ) and lithium chloride (LiC1) on CNPaselI gene expression. C6 glioma cells were 
grown for 1 week under 1.0 mM NaC1, 0.5 mM sodium valproate, 0.05 mM carbamazepine and different concentration of LiC1 (0.04, 0.2 and 
1.0 mM). Control cells (con.) were treated identically but without addition of drugs. Total RNA (5 p.g) was analyzed by slot blot hybridization 
using 32p-dCTP labeled probe of CNPaselI. Autoradiograms were quantitated by densitometry. Results are the mean + S.E.M. of triplicate de- 
terminations. *P<0.05, **P<0.01, when compared with control cells. 
sis commonly present with mood instability reminiscent of 
BD, which in some cases may respond to mood stabilizing 
medications uch as lithium [44,45]. Furthermore, a relation- 
ship between multiple sclerosis and depression or mania has 
been recognized in clinical and epidemiological studies [46,47]. 
Using magnetic resonance imaging several research groups 
have reported increased white matter signal intensity and de- 
creased white matter volume in patients with BD compared 
with age-matched control subjects which illustrates the poten- 
tial significance of white matter abnormalities to this illness 
[48-50]. The increased expression of CNPasel l  by lithium 
treatment suggests that this treatment may have an effect on 
the process of myelination (and possibly neurodevelopment) 
which may have implications for BD in which white matter 
abnormalities may occur. It is not known at present what 
effect lithium treatment has on gene expression in neuronal 
cell lines or in mature brain, so the significance of the present 
results obtained in a glial cell line will await the result of 
future investigations. Further work clearly needs to be under- 
taken to clarify the potential significance of these novel find- 
ings. 
In conclusion, chronic lithium treatment leads to the in- 
creased expression of several mRNAs  in C6 glioma cells, of 
which one can at present be identified. The results of the 
present study demonstrate the potential utility of differential 
display PCR to study the mechanisms of action of psycho- 
tropic drugs and also in the identification of pathophysiologic 
changes in psychiatric disorders such as BD. Alterations in 
gene expression in brain by lithium are consistent with the 
current focus on the action of psychotropic drugs on long- 
term adaptational changes in brain due to alterations in gene 
expression rather than in changes in the level of specific 
monoamines or their metabolites. 
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